Literature DB >> 17100150

Treatment of benign diseases with megavoltage X-ray beams: is there a risk for gonadal damage?

G Kokona1, M Mazonakis, H Varveris, E Liraraki, J Damilakis.   

Abstract

AIMS: To measure the testicular and ovarian doses and to assess the risk for gonadal damage to patients treated with megavoltage X-ray beams for benign diseases.
MATERIALS AND METHODS: Radiation therapy of benign diseases was simulated on an anthropomorphic phantom with a 6MV photon beam. The gonadal dose was calculated during the irradiation of heterotopic ossification, liver and vertebra haemangiomas, bone cysts, Graves' ophthalmopathy and gynaecomastia. Dose measurements were carried out using thermoluminescent dosimeters. For the radiotherapy of heterotopic ossification, the effect of using lead blocks to spare lymphatic drainage on the gonadal dose was determined.
RESULTS: The ovarian and testicular total doses were found to be 2.00-680 and 2.0-39.0 mGy, respectively, depending on the gonadal location in respect to the treatment volume. The introduction of blocks into the primary beam resulted in an increase in gonadal dose up to a factor of 1.7. The radiation-induced risk of hereditary disorders in future generations was (1.0-40.8) x 10(-4) and (1.0-23.4) x 10(-4) for women and men, respectively.
CONCLUSIONS: Radiation therapy of benign diseases always resulted in gonadal doses below 1 Gy and therefore there was no risk for permanent gonadal failure. The excess risk of radiation-induced hereditary disorders in offspring was low in comparison with the natural frequency of these effects. However, there was a considerable excess in risk after irradiation in the hip bone.

Entities:  

Mesh:

Year:  2006        PMID: 17100150     DOI: 10.1016/j.clon.2006.07.013

Source DB:  PubMed          Journal:  Clin Oncol (R Coll Radiol)        ISSN: 0936-6555            Impact factor:   4.126


  3 in total

1.  Testicular Dose During Prophylaxis of Heterotopic Ossification with Radiation Therapy.

Authors:  Waleed F Mourad; John K Ma; Satyaseelan Packianathan; Weisi Yan; Sherif G Shaaban; Edward M Marchan; Lamiaa E Abdallah; Rei He; Paul N Mobit; Chunli Claus Yang; Srinivasan Vijayakumar
Journal:  In Vivo       Date:  2017 May-Jun       Impact factor: 2.155

2.  Perioperative high-dose-rate brachytherapy in the treatment of recurrent malignant gliomas.

Authors:  Maria Grazia Fabrini; Franco Perrone; Lucia De Franco; Francesco Pasqualetti; Silvia Grespi; Riccardo Vannozzi; Luca Cionini
Journal:  Strahlenther Onkol       Date:  2009-08-04       Impact factor: 3.621

Review 3.  Radiotherapy for aneurysmal bone cysts : A rare indication.

Authors:  Khaled Elsayad; Jan Kriz; Heinrich Seegenschmiedt; Detlef Imhoff; Reinhard Heyd; Hans Theodor Eich; Oliver Micke
Journal:  Strahlenther Onkol       Date:  2016-12-12       Impact factor: 3.621

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.